Unity Biotechnology (NASDAQ:UBX Get Rating) had its price target reduced by Citigroup from $15.00 to $5.00 in a research report released on Tuesday, The Fly reports. Citigroup currently has a buy rating on the stock. Other equities analysts have also recently issued reports about the stock. ...

UBX1325 monotherapy did not achieve non-inferiority through 24 weeks due, in part, to an unexpected 3.5 letter gain in the anti-VEGF control arm UBX1325 maintained visual acuity in patients with ongoing active disease through 24 weeks with less than one letter mean decrease from baseline 52% of ...

Unity Biotechnology (NASDAQ:UBX Get Rating)s stock had its buy rating restated by equities researchers at HC Wainwright in a report released on Thursday, Benzinga reports. They presently have a $10.00 price target on the stock. HC Wainwrights price target suggests...

SOUTH SAN FRANCISCO, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the Companys Management will provide a corporate update and participate in...

-Investor call with retinal expert Robert B. Bhisitkul, M.D., Ph.D., to be held on Tuesday, February 14, 2023 at 7:00 a.m. PT/ 10:00 a.m. ET- -Complete 16- and 24-week safety and efficacy data from phase 2 ENVISION study in wet AMD expected in Q1 2023- SOUTH SAN FRANCISCO, Calif., Feb. 09, 2023 (...